Drug Induced Liver Injury (DILI) is a major cause of attrition in late-stage drug development, accounting for 13% of cases of acute liver failure. This is largely due to a lack of accurate, reproducible models capable of predicting DILI in early development. Currently, a combination of both in vivo animal models, and in vitro human […]

Hepatotoxicity (liver cell toxicity) is one of the major causes of drug attrition during clinical development and withdrawal post-marketing. Drug Induced Liver Injury (DILI), results in significant late-stage attrition for drugs of all types; 70% of marketed drugs are cleared through the liver making it the primary organ drug metabolism and pharmacokinetic (DMPK) scientists seek […]

Drug metabolism and pharmacokinetic (DMPK) scientists are tasked with the determination of various parameters to predict human PK. Their goal is to identify drug candidates with PK properties that are both effective and safe for use as a therapeutic treatment. One such parameter is clearance (CL), or the rate of drug cleared from plasma over […]